Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.185
-0.065 (-2.89%)
At close: Apr 28, 2026, 4:00 PM EDT
2.190
+0.005 (0.23%)
After-hours: Apr 28, 2026, 4:01 PM EDT
Allogene Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | 0.02 | 0.1 | 0.16 | 114.09 | |
| Revenue Growth (YoY) | - | -76.84% | -39.10% | -99.86% | - | |
| Cost of Revenue | 150.15 | 192.3 | 242.91 | 256.39 | 220.18 | |
| Gross Profit | -150.15 | -192.28 | -242.82 | -256.23 | -106.09 | |
| Selling, General & Admin | 56.78 | 65.21 | 71.67 | 79.31 | 74.11 | |
| Operating Expenses | 56.78 | 65.21 | 71.67 | 79.31 | 74.11 | |
| Operating Income | -206.93 | -257.48 | -314.49 | -335.54 | -180.19 | |
| Interest Expense | -1.08 | -0.18 | - | - | - | |
| Interest & Investment Income | 19.29 | 20.15 | 18.31 | 4.57 | 1.71 | |
| Earnings From Equity Investments | - | -1.69 | -10.67 | -12.88 | -4.09 | |
| Other Non Operating Income (Expenses) | 0.22 | -0.28 | -0.16 | 3.44 | 0.52 | |
| EBT Excluding Unusual Items | -188.5 | -239.47 | -307.02 | -340.41 | -182.05 | |
| Gain (Loss) on Sale of Investments | - | -1.96 | -7 | - | - | |
| Asset Writedown | -2.38 | -15.72 | -13.25 | - | - | |
| Pretax Income | -190.89 | -257.15 | -327.27 | -340.41 | -182.05 | |
| Income Tax Expense | - | 0.44 | - | - | - | |
| Net Income | -190.89 | -257.59 | -327.27 | -340.41 | -182.05 | |
| Net Income to Common | -190.89 | -257.59 | -327.27 | -340.41 | -182.05 | |
| Shares Outstanding (Basic) | 221 | 195 | 157 | 143 | 136 | |
| Shares Outstanding (Diluted) | 221 | 195 | 157 | 143 | 136 | |
| Shares Change (YoY) | 13.25% | 24.14% | 9.63% | 5.39% | 12.84% | |
| EPS (Basic) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | |
| EPS (Diluted) | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | |
| Free Cash Flow | -149.63 | -200.99 | -239.25 | -225.71 | -206.26 | |
| Free Cash Flow Per Share | -0.68 | -1.03 | -1.52 | -1.58 | -1.52 | |
| Gross Margin | - | - | - | - | -92.99% | |
| Operating Margin | - | -1170372.73% | -331044.21% | -215087.18% | -157.94% | |
| Profit Margin | - | -1170863.64% | -344489.47% | -218214.10% | -159.57% | |
| Free Cash Flow Margin | - | -913609.09% | -251841.05% | -144685.90% | -180.79% | |
| EBITDA | -194.57 | -243.84 | -300.29 | -321.24 | -169.74 | |
| EBITDA Margin | - | - | - | - | -148.78% | |
| D&A For EBITDA | 12.36 | 13.64 | 14.2 | 14.3 | 10.45 | |
| EBIT | -206.93 | -257.48 | -314.49 | -335.54 | -180.19 | |
| EBIT Margin | - | - | - | - | -157.94% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.